Get started
Author

Nagalaxmi Vemalapally

ORCID: 0009-0001-1970-5460
Observed ORCID: 0009-0001-1970-5460
OpenAlex ID: A5085644960
Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2023 · Xiaoqing Cheng, Yirui Sun, et al. · Cancer Research · 36
PDF
Abstract PS4-13: Irreversible inhibition of HER2 activating mutations with neratinib enhances the pre-clinical efficacy of trastuzumab emtansine and trastuzumab deruxtecan
2021 · Ron Bose, Shunqiang Li, et al. · Cancer Research · 7
Development of Pediatric Model of Hematopoietic Acute Radiation Syndrome (h-ars) and Countermeasure Testing Using the Göttingen Minipig
2017 · Amandeep Kaur, Nagalaxmi Vemalapally, et al. · RAD Association Journal · 7
PDF
Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids
2023 · Shunqiang Li, Tina M. Primeau, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Table S1 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Table S2 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Table S5 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Table S6 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Table S4 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Table S3 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
Figures S1-S8 from Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
2025 · Xiaoqing Cheng, Yirui Sun, et al.
PDF
Data from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S1 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Figures S1-S8 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S4 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S5 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S3 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S2 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S2 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S1 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S6 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S5 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Table S4 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Figures S1-S8 from Breast cancer mutations HER2 V777L and PIK3CA H1047R activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistance.
2024 · Xiaoqing Cheng, Yirui Sun, et al.
Works count: 45
Citation count: 52
H-index: 3
I10-index: 1
Year
Topic
Type